https://www.openbell.ai/ 2026-09-24T11:48:13.509Z hourly 1.0 https://www.openbell.ai/support 2026-09-24T11:48:13.509Z monthly 0.7 https://www.openbell.ai/privacy 2026-09-24T11:48:13.509Z monthly 0.5 https://www.openbell.ai/terms 2026-09-24T11:48:13.509Z monthly 0.5 https://www.openbell.ai/feed.json 2026-09-24T11:48:13.509Z hourly 0.8 https://www.openbell.ai/news/DG:1790250411186 2026-09-24T11:46:51.186Z daily 0.9 https://cdn.brandfetch.io/DG/w/400/h/400?c=1idopYfmtR7ZKg8QMud HSBC Upgrades Dollar General to Buy, Raises Price Target to $160 HSBC analyst Daniela Bretthauer has upgraded Dollar General (NYSE: DG) from a 'Hold' to a 'Buy' rating. Additionally, the price target for the stock has been raised from $125 to $160. https://www.openbell.ai/news/SKYQ:1790250410961 2026-09-24T11:46:50.961Z daily 0.9 https://cdn.brandfetch.io/SKYQ/w/400/h/400?c=1idopYfmtR7ZKg8QMud Sky Quarry Receives Nevada Regulator's Air Permit To Restart Its Eagle Springs Refinery Sky Quarry Inc. (NASDAQ: SKYQ) has received an air permit from the Nevada Division of Environmental Protection, allowing it to restart operations at its Eagle Springs Refinery located near Ely, Nevada. The refinery is managed by the company's wholly owned subsidiary, Foreland Refining Corporation. https://www.openbell.ai/news/QNCX:1790250094750 2026-09-24T11:41:34.750Z daily 0.9 https://cdn.brandfetch.io/QNCX/w/400/h/400?c=1idopYfmtR7ZKg8QMud Rodman & Renshaw Initiates Coverage On Quince Therapeutics with Buy Rating, Announces Price Target of $70 Rodman & Renshaw analyst Seema Sheoran has initiated coverage on Quince Therapeutics (NASDAQ: QNCX) with a Buy rating. The firm has set a price target of $70 for the stock. https://www.openbell.ai/news/TTRX:1790249939022 2026-09-24T11:38:59.022Z daily 0.9 https://cdn.brandfetch.io/TTRX/w/400/h/400?c=1idopYfmtR7ZKg8QMud LUCID CAPITAL MARKETS Initiates Coverage On Turn Therapeutics with Buy Rating, Announces Price Target of $24 LUCID CAPITAL MARKETS has initiated coverage on Turn Therapeutics (NASDAQ: TTRX) with a Buy rating. The firm has set a price target of $24 for the stock. https://www.openbell.ai/news/CRWV:1790249739955 2026-09-24T11:35:39.955Z daily 0.9 https://cdn.brandfetch.io/CRWV/w/400/h/400?c=1idopYfmtR7ZKg8QMud JP Morgan Upgrades CoreWeave to Overweight, Raises Price Target to $125 JP Morgan analyst Samik Chatterjee has upgraded CoreWeave (NASDAQ: CRWV) from Neutral to Overweight. The price target for the stock has been raised from $120 to $125. https://www.openbell.ai/news/CRWV:1790249738452 2026-09-24T11:35:38.452Z daily 0.9 https://cdn.benzinga.com/files/images/story/2026/09/24/Los-Angeles--California---July-7-2025-Co.jpg?width=250&height=187 CoreWeave Trending: A New AI Customer and UBS' Contrarian $120 Call CoreWeave Inc. (NASDAQ: CRWV) announced a new multi-year customer agreement with Harell Data to host its biotech AI platform on CoreWeave Cloud, allowing for efficient training and inference workloads without data extraction. UBS initiated coverage of CoreWeave with a Buy rating and a price target of $120, citing strong demand for AI computing power and an upward trend in revenue per gigawatt of capacity. As of the latest data, CoreWeave shares are trading 1.40% higher at $88.11. https://www.openbell.ai/news/DRI:1790249693994 2026-09-24T11:34:53.994Z daily 0.9 https://cdn.brandfetch.io/DRI/w/400/h/400?c=1idopYfmtR7ZKg8QMud Darden Restaurants shares are trading lower after the company reported worse-than-expected Q1 financial results. openbell Financial News https://www.openbell.ai/news/P:1790249663105 2026-09-24T11:34:23.105Z daily 0.9 https://cdn.brandfetch.io/P/w/400/h/400?c=1idopYfmtR7ZKg8QMud Everpure shares are trading higher after the company issued preliminary FY28 revenue results and reaffirmed its FY27 revenue guidance. Also, Needham maintained a Buy rating on the stock and raised its price target from $140 to $150. openbell Financial News https://www.openbell.ai/news/PFSA:1790249626063 2026-09-24T11:33:46.063Z daily 0.9 https://cdn.brandfetch.io/PFSA/w/400/h/400?c=1idopYfmtR7ZKg8QMud Profusa Says It Received Positive Quality System Certification Decision From EU Certifier GMED; Lumee CE Mark Still Pending openbell Financial News https://www.openbell.ai/news/ORKA:1790249554121 2026-09-24T11:32:34.121Z daily 0.9 https://cdn.brandfetch.io/ORKA/w/400/h/400?c=1idopYfmtR7ZKg8QMud HC Wainwright & Co. Reiterates Buy on Oruka Therapeutics, Maintains $120 Price Target HC Wainwright & Co. analyst Mitchell S. Kapoor has reiterated a Buy rating on Oruka Therapeutics (NASDAQ: ORKA) and maintained a price target of $120 for the stock. https://www.openbell.ai/news/MAZE:1790249480590 2026-09-24T11:31:20.590Z daily 0.9 https://cdn.brandfetch.io/MAZE/w/400/h/400?c=1idopYfmtR7ZKg8QMud HC Wainwright & Co. Reiterates Buy on Maze Therapeutics, Maintains $110 Price Target HC Wainwright & Co. analyst Ananda Ghosh has reiterated a Buy rating on Maze Therapeutics (NASDAQ: MAZE) and maintained a price target of $110 for the stock. https://www.openbell.ai/news/QCOM:1790249461225 2026-09-24T11:31:01.225Z daily 0.9 https://cdn.brandfetch.io/QCOM/w/400/h/400?c=1idopYfmtR7ZKg8QMud Qualcomm Renew Global Patent License Deal With Apple, Effective April 1, 2027 Qualcomm Incorporated has renewed its global patent license agreement with Apple, which will take effect on April 1, 2027. This renewal signifies the continuation of their partnership in technology licensing. https://www.openbell.ai/news/EFOR:1790248827271 2026-09-24T11:20:27.271Z daily 0.9 https://cdn.brandfetch.io/EFOR/w/400/h/400?c=1idopYfmtR7ZKg8QMud Everforth's ECS Unit Awarded Three-Year Contract Expansion With A $148M Ceiling To Support The Chief Digital And AI Office’s Secure Unclassified Network Everforth's ECS unit has been awarded a three-year contract expansion with a ceiling of $148 million to support the Chief Digital and AI Office’s Secure Unclassified Network (SUNet). This expansion allows Everforth ECS to manage and maintain the operational environment while transitioning mission capabilities to the future SUNet architecture. Additionally, the company has been selected to prototype SUNet 2.0, aimed at providing a secure digital environment for the Department of War and its mission partners to develop and validate emerging AI/ML capabilities. https://www.openbell.ai/news/NEOV:1790248758376 2026-09-24T11:19:18.376Z daily 0.9 https://cdn.brandfetch.io/NEOV/w/400/h/400?c=1idopYfmtR7ZKg8QMud Needham Reiterates Buy on NeoVolta, Maintains $8 Price Target Needham analyst Sean Milligan has reiterated a 'Buy' rating on NeoVolta (NASDAQ: NEOV) and maintained a price target of $8 for the company's stock. No additional financial figures or strategic changes were mentioned in the article. https://www.openbell.ai/news/AUR:1790248630749 2026-09-24T11:17:10.749Z daily 0.9 https://cdn.brandfetch.io/AUR/w/400/h/400?c=1idopYfmtR7ZKg8QMud Needham Reiterates Buy on Aurora Innovation, Maintains $13 Price Target Needham analyst Chris Pierce has reiterated a Buy rating on Aurora Innovation (NASDAQ: AUR) and maintained a price target of $13 for the stock. https://www.openbell.ai/news/FRVO:1790248553751 2026-09-24T11:15:53.751Z daily 0.9 https://cdn.brandfetch.io/FRVO/w/400/h/400?c=1idopYfmtR7ZKg8QMud Bernstein Reiterates Outperform on Fervo Energy, Maintains $47 Price Target Bernstein analyst Sunaina Ocalan has reiterated an 'Outperform' rating on Fervo Energy (NASDAQ: FRVO) and has maintained a price target of $47 for the stock. https://www.openbell.ai/news/GOOGL:1790248441469 2026-09-24T11:14:01.469Z daily 0.9 https://cdn.benzinga.com/files/images/story/2026/09/24/Portland--Or--Usa---Feb-8--2024-Google-G.jpg?width=250&height=187 Google’s Gemini 4 Could Launch 'Much Earlier’ Than Year-End, Says DeepMind Exec as AI Battle With OpenAI, Anthropic, Meta Heats up Alphabet Inc.'s Google is nearing the launch of its latest AI model, Gemini 4, which is expected to debut 'much earlier' than the end of the year, according to DeepMind's senior VP Koray Kavukcuoglu. This development comes as Google competes with companies like OpenAI, Anthropic, and Meta Platforms in the AI sector. Year-to-date, Google's stock (GOOG) has increased by 6.75%, though it closed 3.58% lower at $334.98 on Wednesday, with a slight dip of 0.58% in premarket trading on Thursday. https://www.openbell.ai/news/VEEV:1790248309211 2026-09-24T11:11:49.211Z daily 0.9 https://cdn.brandfetch.io/VEEV/w/400/h/400?c=1idopYfmtR7ZKg8QMud Veeva Systems Announces AI Study Builder Agent To Configure Clinical Studies From Protocols, Delivered As Claude Cowork Plugin openbell Financial News https://www.openbell.ai/news/XE:1790248221428 2026-09-24T11:10:21.428Z daily 0.9 https://cdn.brandfetch.io/XE/w/400/h/400?c=1idopYfmtR7ZKg8QMud X-Energy Unit TRISO-X Completes Vertical Construction At TX-1, Its Advanced Nuclear Fuel Fabrication Facility In Oak Ridge, Tennessee X-Energy's unit TRISO-X has completed vertical construction of its TX-1 advanced nuclear fuel fabrication facility in Oak Ridge, Tennessee, marking a significant milestone in the project. The 214,000-square-foot facility is set to produce approximately 700,000 TRISO-X fuel pebbles annually, equivalent to 5 metric tons of uranium, supporting up to 11 Xe-100 reactors. The U.S. Nuclear Regulatory Commission has granted a 40-year Special Nuclear Material License for TX-1, which is the first commercial-scale advanced U.S. nuclear fuel fabrication facility built in over 50 years. The company is also expanding its operations and partnerships to meet growing demand for nuclear energy. https://www.openbell.ai/news/VTGN:1790248188516 2026-09-24T11:09:48.516Z daily 0.9 https://cdn.brandfetch.io/VTGN/w/400/h/400?c=1idopYfmtR7ZKg8QMud Vistagen Presents Exploratory Data At Psych Congress 2026 Highlighting Potential Efficacy Signal For Phase 3 Fasedienol Nasal Spray In Patients With Very Severe Social Anxiety Disorder Vistagen (NASDAQ: VTGN) presented positive exploratory data at Psych Congress 2026, indicating a potential efficacy signal for its Phase 3 product candidate, fasedienol nasal spray, in patients with very severe social anxiety disorder. The research involved a public speaking challenge study and showed that participants with a Liebowitz Social Anxiety Scale (LSAS) score of 95 or higher experienced improvements in anxiety symptoms after treatment with fasedienol compared to placebo. The findings were supported by analyses from two randomized, double-blind, placebo-controlled clinical trials. https://www.openbell.ai/news/OGC:1790248125538 2026-09-24T11:08:45.538Z daily 0.9 https://cdn.brandfetch.io/OGC/w/400/h/400?c=1idopYfmtR7ZKg8QMud OceanaGold Reports Drill Results Including 6.3 Meters Of 97.2 g/t Gold At Wharekirauponga In New Zealand openbell Financial News https://www.openbell.ai/news/MESO:1790248011121 2026-09-24T11:06:51.121Z daily 0.9 https://cdn.brandfetch.io/MESO/w/400/h/400?c=1idopYfmtR7ZKg8QMud Mesoblast Receives FDA Approval To Implement A New Potency Assay, T-Cell Proliferation Inhibition Bioassay, For Release And Stability Monitoring Of All New Commercial Product Lots Of Its Mesenchymal Stromal Cell Product Ryoncil Mesoblast has received FDA approval to implement a new potency assay, the T-Cell Proliferation Inhibition Bioassay (TIBA), for the release and stability monitoring of its mesenchymal stromal cell product, RYONCIL. This assay will enhance the sensitivity to detect potency shifts during manufacturing changes and will be used alongside existing potency assays. RYONCIL is the first FDA-approved allogeneic MSC product for patients with steroid-refractory acute graft versus host disease aged 2 months or older, highlighting its significance in the market. https://www.openbell.ai/news/LGND:1790247927893 2026-09-24T11:05:27.893Z daily 0.9 https://cdn.brandfetch.io/LGND/w/400/h/400?c=1idopYfmtR7ZKg8QMud Ligand Announces Up To $47M Financing For CAR-T Developer AvenCell, Including Up To $41M For Pipeline Royalties openbell Financial News https://www.openbell.ai/news/P:1790247925827 2026-09-24T11:05:25.827Z daily 0.9 https://cdn.brandfetch.io/P/w/400/h/400?c=1idopYfmtR7ZKg8QMud Needham Maintains Buy on Everpure, Raises Price Target to $150 Needham analyst Matthew Calitri has maintained a 'Buy' rating on Everpure (NYSE: P) and increased the price target from $140 to $150. This adjustment reflects positive expectations for the company's performance in the market. https://www.openbell.ai/news/AMZN:1790247911312 2026-09-24T11:05:11.312Z daily 0.9 https://cdn.benzinga.com/files/images/story/2026/09/24/Aerial-Data-Center-Exterior-Infrastructu.jpg?width=250&height=187 AI’s Deflationary Product Cannot Support the $5 Trillion Bill The costs associated with artificial intelligence are decreasing rapidly, with inference-token costs dropping approximately 47% per quarter. In contrast, major tech companies, including Alphabet, Microsoft, Amazon, Meta, and Oracle, are projected to spend over $5 trillion on data centers in the coming years. Despite this investment, economists report minimal productivity gains from AI, with a Stanford survey indicating that 90% of executives saw no increase in productivity over three years. The financial viability of these investments is under scrutiny, as companies must achieve significant productivity improvements to justify their capital expenditures. https://www.openbell.ai/news/JAGU:1790247901227 2026-09-24T11:05:01.227Z daily 0.9 https://cdn.brandfetch.io/JAGU/w/400/h/400?c=1idopYfmtR7ZKg8QMud Jaguar Uranium Reports Up To 3,570 ppm Rare Earth Oxides From Resampled Drill Core At Colombia's Berlin Project openbell Financial News https://www.openbell.ai/news/DY:1790247770874 2026-09-24T11:02:50.874Z daily 0.9 https://cdn.brandfetch.io/DY/w/400/h/400?c=1idopYfmtR7ZKg8QMud Cantor Fitzgerald Reiterates Overweight on Dycom Industries, Maintains $476 Price Target Cantor Fitzgerald analyst Manish A. Somaiya has reiterated an Overweight rating on Dycom Industries (NYSE: DY) and maintained a price target of $476 for the stock. No specific financial figures or recent strategic changes were mentioned in the article. https://www.openbell.ai/news/MSCL:1790247718925 2026-09-24T11:01:58.925Z daily 0.9 https://cdn.brandfetch.io/MSCL/w/400/h/400?c=1idopYfmtR7ZKg8QMud FDA Clears Satellos Bioscience’s IND Application For Forazapadin For Treatment Of Facioscapulohumeral Muscular Dystrophy Satellos Bioscience Inc. has received FDA clearance for its IND application for forazapadin, aimed at treating facioscapulohumeral muscular dystrophy (FSHD). The company plans to start a Phase 2 clinical study in FSHD in Q4 2026. Additionally, the FSHD Canada Foundation will provide up to US$5 million in non-dilutive financing for the clinical development of forazapadin. https://www.openbell.ai/news/SNX:1790247713077 2026-09-24T11:01:53.077Z daily 0.9 https://cdn.brandfetch.io/SNX/w/400/h/400?c=1idopYfmtR7ZKg8QMud TD Synnex Sees Q4 Adj EPS $5.65-$6.15 vs $4.87 Est; Sees Sales $21.800B-$22.600B vs $19.363B Est TD Synnex (NYSE: SNX) projects its Q4 adjusted earnings per share (EPS) to be between $5.65 and $6.15, surpassing the analyst estimate of $4.87. The company anticipates sales in the range of $21.800 billion to $22.600 billion, compared to the analyst estimate of $19.363 billion. https://www.openbell.ai/news/BB:1790247682973 2026-09-24T11:01:22.973Z daily 0.9 https://cdn.brandfetch.io/BB/w/400/h/400?c=1idopYfmtR7ZKg8QMud BlackBerry Raises FY2027 Adj EPS Guidance from $0.16-$0.20 to $0.19-$0.22 vs $0.19 Est; Raises FY2027 Sales Guidance from $594.000M-$621.000M to $616.000M-$636.000M vs $614.592M Est BlackBerry has raised its FY2027 adjusted EPS guidance from a range of $0.16-$0.20 to $0.19-$0.22, aligning with the analyst estimate of $0.19. Additionally, the company increased its FY2027 sales outlook from $594 million-$621 million to $616 million-$636 million, surpassing the analyst estimate of $614.592 million. https://www.openbell.ai/news/SNX:1790247649905 2026-09-24T11:00:49.905Z daily 0.9 https://cdn.brandfetch.io/SNX/w/400/h/400?c=1idopYfmtR7ZKg8QMud TD Synnex Q3 Adj. EPS $5.68 Beats $4.70 Estimate, Sales $21.558B Beat $18.909B Estimate TD Synnex (NYSE: SNX) reported Q3 adjusted earnings per share of $5.68, surpassing the analyst estimate of $4.70 by 20.85%, and marking a 58.66% increase from $3.58 per share a year ago. The company's quarterly sales reached $21.558 billion, exceeding the $18.909 billion estimate by 14.01%, and reflecting a 37.75% increase from $15.650 billion in the same quarter last year. https://www.openbell.ai/news/SHLE:1790247608817 2026-09-24T11:00:08.817Z daily 0.9 https://cdn.benzinga.com/files/images/story/2026/09/24/Offshore-Oil-And-Gas-Jackup-Platform-In-.jpg?width=250&height=187 Oil and Gas PE Deals Plunge 60% as War, Price Shocks and Uncertainty Fuel Pullback Private equity investment in oil and gas deals fell 60% in Q2 2026, with only 16 transactions valued at $3.4 billion, compared to 56 deals worth $13.4 billion in the first half of 2025. The decline is attributed to geopolitical uncertainties, particularly the wars in Iran and Ukraine, which have caused volatile commodity prices. Despite this, strategic buyers like Shell PLC, which agreed to acquire ARC Resources for $16.4 billion, continue to pursue acquisitions in the energy sector, particularly in natural gas and LNG assets. https://www.openbell.ai/news/IONS:1790247570121 2026-09-24T10:59:30.121Z daily 0.9 https://cdn.brandfetch.io/IONS/w/400/h/400?c=1idopYfmtR7ZKg8QMud HC Wainwright & Co. Reiterates Buy on Ionis Pharmaceuticals, Maintains $100 Price Target HC Wainwright & Co. analyst Mitchell S. Kapoor has reiterated a Buy rating on Ionis Pharmaceuticals (NASDAQ: IONS) and maintained a price target of $100 for the stock. https://www.openbell.ai/news/BB:1790247534972 2026-09-24T10:58:54.972Z daily 0.9 https://cdn.brandfetch.io/BB/w/400/h/400?c=1idopYfmtR7ZKg8QMud BlackBerry Q2 Adj. EPS $0.07 Beats $0.04 Estimate, Sales $163.300M Beat $145.634M Estimate BlackBerry (NYSE: BB) reported Q2 adjusted earnings per share of $0.07, surpassing the analyst estimate of $0.04 by 75%, and reflecting a 75% increase from $0.04 per share in the same quarter last year. The company also achieved quarterly sales of $163.300 million, exceeding the expected $145.634 million by 12.13%, and marking a 26% increase from $129.600 million in the prior year. https://www.openbell.ai/news/AMZN:1790247477811 2026-09-24T10:57:57.811Z daily 0.9 https://cdn.brandfetch.io/AMZN/w/400/h/400?c=1idopYfmtR7ZKg8QMud 'DeepSeek Aims to Close $7.5 Billion Funding Round by End-October' - The Information DeepSeek is targeting to close a $7.5 billion funding round by the end of October. This funding is expected to bolster the company's growth and expansion plans. The move comes as DeepSeek seeks to enhance its market position amidst increasing competition in the tech industry. https://www.openbell.ai/news/AMZN:1790247353456 2026-09-24T10:55:53.456Z daily 0.9 https://cdn.brandfetch.io/AMZN/w/400/h/400?c=1idopYfmtR7ZKg8QMud 'DeepSeek Aims to Close $7.5 Billion Funding Round by End-October' - The In DeepSeek is targeting to finalize a $7.5 billion funding round by the end of October 2023. This significant capital raise is expected to enhance the company's growth and market position. The funding round is part of DeepSeek's strategic initiatives to expand its operations and capabilities. https://www.openbell.ai/news/LLY:1790247295318 2026-09-24T10:54:55.318Z daily 0.9 https://cdn.brandfetch.io/LLY/w/400/h/400?c=1idopYfmtR7ZKg8QMud The FDA Approves Eli Lilly's Onswik (Insulin Efsitora Alfa-gobe) For Type 2 Diabetes Eli Lilly and Company has received FDA approval for Onswik™ (insulin efsitora alfa-gobe), a once-weekly basal insulin for adults with type 2 diabetes, aimed at controlling high blood sugar alongside diet and exercise. This approval follows previous endorsements from the European Medicines Agency, Mexico's COFEPRIS, and Japan's PMDA. The approval is based on the QWINT Phase 3 clinical trials involving over 3,400 adults, demonstrating non-inferior A1C reduction compared to existing daily basal insulins. Onswik will be available in two concentrations in the U.S. in the coming months. https://www.openbell.ai/news/MRK:1790246911323 2026-09-24T10:48:31.323Z daily 0.9 https://cdn.brandfetch.io/MRK/w/400/h/400?c=1idopYfmtR7ZKg8QMud Merck Says Topline Data From Phase 2b/3 BRUNELLO Trial Of Remigromig (MK-3000, Formerly EYE103) For Diabetic Macular Edema Met Its Primary Endpoint Merck (NYSE: MRK) announced that the Phase 2b/3 BRUNELLO trial for remigromig (MK-3000) in diabetic macular edema met its primary endpoint, demonstrating non-inferiority to the active control ranibizumab in improving best-corrected visual acuity at 52 weeks. Both doses of remigromig were generally well tolerated, although higher rates of adverse events were noted compared to ranibizumab. The results will be presented at the American Academy of Ophthalmology Annual Meeting on October 10. Merck is also advancing its ophthalmology pipeline with additional studies for remigromig and other investigational treatments. https://www.openbell.ai/news/IONQ:1790246746196 2026-09-24T10:45:46.196Z daily 0.9 https://cdn.benzinga.com/files/images/story/2026/09/24/Munich--Bavaria--Germany---March-31-2023.jpg?width=250&height=187 IonQ Removes Major Quantum Barrier, Driving Investor Debate Over Commercial Timelines IonQ Inc. (NYSE: IONQ) has made a significant advancement in quantum computing by demonstrating real-time error correction, which analysts view as a crucial step towards commercial viability. This breakthrough has sparked investor discussions regarding the timelines for practical quantum computing, with some experts suggesting that IonQ's innovation could lead to faster commercialization than previously anticipated. IonQ's stock was down 2.97% to $41.27 in premarket trading, indicating market reactions to the news. https://www.openbell.ai/news/META:1790246540398 2026-09-24T10:42:20.398Z daily 0.9 https://cdn.benzinga.com/files/images/story/2026/09/24/Meta-Platforms-Menlo-Park--Ca--Usa---Apr.jpg?width=250&height=187 Meta’s Muse AI Has Wall Street Seeing Billion-Dollar Possibilities Meta Platforms Inc. is seeing increased interest from Wall Street regarding its AI strategy, particularly with the Muse AI platform, which is gaining users and opening new revenue opportunities in subscriptions, advertising, and small-business services. Analysts from Jefferies and Evercore predict rapid adoption of Muse, potentially reaching 100 million users within six to twelve months. Goldman Sachs highlights that Muse could significantly impact Meta's valuation and infrastructure demand, estimating that 100 million users could require 1.6 to 1.7 gigawatts of compute capacity, necessitating around $50 billion in capital spending. Despite this optimism, Meta's stock was down 2.60% to $724.77 in premarket trading. https://www.openbell.ai/news/RPM:1790246523923 2026-09-24T10:42:03.923Z daily 0.9 https://cdn.benzinga.com/files/images/story/2026/09/24/Konskie--Poland---December-03--2024-Rpm-.jpg?width=250&height=187 RPM Earnings Are Imminent; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call RPM International Inc. is set to release its first-quarter earnings report on October 6, with analysts expecting earnings of $1.95 per share, an increase from $1.88 per share in the previous year. The consensus revenue estimate is $2.22 billion, up from $2.11 billion reported last year. Following a recent earnings report that exceeded expectations, RPM shares fell 1% to close at $100.06. Analysts have varied ratings and price target adjustments, with Morgan Stanley reducing its target from $121 to $117, while BMO Capital raised its target from $143 to $151. https://www.openbell.ai/news/RPM:1790246504215 2026-09-24T10:41:44.215Z daily 0.9 https://cdn.brandfetch.io/RPM/w/400/h/400?c=1idopYfmtR7ZKg8QMud RPM Earnings Are Imminent; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call RPM International Inc. (NYSE: RPM) is set to release its first-quarter earnings report on October 6, with analysts expecting earnings of $1.95 per share and revenue of $2.22 billion, compared to $1.88 per share and $2.11 billion in the same quarter last year. Following its better-than-expected fourth-quarter results reported on July 22, RPM shares fell 1% to close at $100.06. Recent analyst updates include Morgan Stanley lowering its price target from $121 to $117, while BMO Capital raised its target from $143 to $151. https://www.openbell.ai/news/CNL:1790246423742 2026-09-24T10:40:23.742Z daily 0.9 https://cdn.brandfetch.io/CNL/w/400/h/400?c=1idopYfmtR7ZKg8QMud Collective Miningn Announces Assay Results For Four Diamond Drill Holes At Its Guayabales Project In Colombia; Results Show New High-Grade Tungsten-Gold Zone And Highlight Continued Exploration Potential Beyond Currently Defined Mineral Resource Model Collective Mining announced significant assay results from four diamond drill holes at its Guayabales Project in Colombia, revealing a new high-grade tungsten-gold zone outside the Apollo Mineral Resource block model. Notably, hole APC150-D4 intersected 8.15 meters grading 14.82 g/t AuEq, marking the company's first tungsten intersection in the area. Additionally, thirteen new high-grade veins were discovered, with some grades significantly exceeding current model estimates. Follow-up drilling is planned to further explore this newly identified mineralization style. https://www.openbell.ai/news/AMST:1790246305757 2026-09-24T10:38:25.757Z daily 0.9 https://cdn.brandfetch.io/AMST/w/400/h/400?c=1idopYfmtR7ZKg8QMud Amesite Announces New Sales Win With Its Minimum Enterprise Pricing Model, Providing Additional Commercial Validation For A Model Designed To Serve Post-acute Care Organizations Amesite Inc. (NASDAQ: AMST) has announced a new sales win utilizing its minimum enterprise pricing model, which is set at $1,099 per month for organizations with a patient census of up to 1,000. This model is expected to yield approximately 85% gross margin and supports scalable revenue growth. The company has reported a 2.4x sequential quarterly revenue increase and a 63% revenue growth from its NurseMagic® Enterprise platform, alongside its largest deployment to date with a 2,700-patient census. The pricing strategy aims to facilitate sales for smaller post-acute care organizations while targeting larger enterprises for greater revenue opportunities. https://www.openbell.ai/news/NKE:1790246264223 2026-09-24T10:37:44.223Z daily 0.9 https://cdn.benzinga.com/files/images/story/2026/09/24/Moffat-Describes-Relaxed-Alertness.jpg?width=250&height=187 Nike Gears Up For Q1 Print; Here Are The Recent Forecast Changes From Wall Street's Most Accurate Analysts Nike, Inc. (NYSE: NKE) is set to release its Q1 earnings on October 1, with analysts predicting earnings of 44 cents per share, a decrease from 49 cents in the same period last year. The expected quarterly revenue is $11.34 billion, down from $11.72 billion reported last year. Following recent analyst downgrades, the stock price closed at $36.05, reflecting a 0.1% decline. https://www.openbell.ai/news/DCO:1790246228696 2026-09-24T10:37:08.696Z daily 0.9 https://cdn.brandfetch.io/DCO/w/400/h/400?c=1idopYfmtR7ZKg8QMud Ducommun Sets Financial Targets; Sales To Reach ~$950M+ By 2027; Adjusted EBITDA Margins To ~18%; Raises Its Acquisition Range By Up To 3–5x, Pursuing Targets In The $300M-$500M Range While Continuing To Pursue Bolt-Ons Ducommun Incorporated (NYSE: DCO) has set a financial target to achieve revenue of approximately $950 million by 2027, with adjusted EBITDA margins expected to reach around 18%. The company is also increasing its acquisition range by 3-5 times, targeting acquisitions in the $300 million to $500 million range while continuing to pursue smaller bolt-on acquisitions. Since the end of 2022, Ducommun's market capitalization has grown from $605 million to $2.6 billion, reflecting a total shareholder return of 245% during this period. https://www.openbell.ai/news/BDSX:1790246160440 2026-09-24T10:36:00.440Z daily 0.9 https://cdn.brandfetch.io/BDSX/w/400/h/400?c=1idopYfmtR7ZKg8QMud Biodesix Announces Progress In Two Collaborative Programs For Tumor-informed And Tumor-naïve Molecular Residual Disease Solutions Biodesix, Inc. (NASDAQ: BDSX) has announced advancements in two collaborative programs for tumor-informed and tumor-naïve Molecular Residual Disease (MRD) solutions, aimed at enhancing cancer monitoring. The tumor-informed solution, developed with Bio-Rad Laboratories, utilizes Droplet Digital PCR technology to detect circulating tumor DNA (ctDNA), while the tumor-naïve solution, in partnership with Thermo Fisher Scientific, employs next-generation sequencing to identify methylated ctDNA without needing tumor tissue. Both solutions will be validated in collaboration with Memorial Sloan Kettering Cancer Center and are designed to be compatible with existing laboratory platforms globally, expanding Biodesix's focus into precision oncology beyond lung diagnostics. https://www.openbell.ai/news/VRT:1790246090878 2026-09-24T10:34:50.878Z daily 0.9 https://cdn.brandfetch.io/VRT/w/400/h/400?c=1idopYfmtR7ZKg8QMud Vertiv To Acquire European Provider Of Fluid Management, Commissioning And Load-Testing Services King Environmental Services; Financial Terms Not Disclosed Vertiv has announced its acquisition of King Environmental Services (KES), a European provider of fluid management, commissioning, and load-testing services, with the aim of enhancing its thermal management services capabilities in the EMEA region. This acquisition follows Vertiv's 2025 purchase of PurgeRite, further expanding its global fluid management services platform. The transaction is expected to close in Q4 2026, with financial terms undisclosed and not anticipated to significantly impact Vertiv's financial results. https://www.openbell.ai/news/CLNE:1790246000934 2026-09-24T10:33:20.934Z daily 0.9 https://cdn.brandfetch.io/CLNE/w/400/h/400?c=1idopYfmtR7ZKg8QMud Clean Energy Fuels Sells $30.7M Of Federal Tax Credits From Seven Of Its Renewable Natural Gas Production Facilities Clean Energy Fuels has successfully sold $30.7 million in federal tax credits from seven of its renewable natural gas (RNG) production facilities, marking its fourth successful transaction in this area. The largest component of the sale is a $26 million investment tax credit from the South Fork Dairy facility in Texas, which began operations in 2025. The credits also include Section 45Z clean fuel production credits generated by projects in Texas, South Dakota, Iowa, and Minnesota, which collectively produced 2.7 million gallons of negative carbon-intensity RNG in 2025. https://www.openbell.ai/news/TYL:1790245658486 2026-09-24T10:27:38.486Z daily 0.9 https://cdn.brandfetch.io/TYL/w/400/h/400?c=1idopYfmtR7ZKg8QMud BTIG Reiterates Buy on Tyler Technologies, Maintains $400 Price Target BTIG analyst Allan Verkhovski has reiterated a Buy rating on Tyler Technologies (NYSE: TYL) and maintained a price target of $400 for the stock. This endorsement suggests confidence in the company's performance and potential growth.